AAAAAA
Results: 1-25/42
Authors:
Avva, R
Vanhemert, RL
Barlogie, B
Munshi, N
Angtuaco, EJ
Citation: R. Avva et al., CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities, AM J NEUROR, 22(4), 2001, pp. 781-785
Authors:
Barlogie, B
Tricot, G
Anaissie, E
Citation: B. Barlogie et al., Thalidomide in the management of multiple myeloma, SEMIN ONCOL, 28(6), 2001, pp. 577-582
Authors:
Barlogie, B
Citation: B. Barlogie, Introduction to therapies in multiple myeloma, SEM HEMATOL, 38(3), 2001, pp. 201-202
Authors:
Barlogie, B
Zangari, M
Spencer, T
Fassas, A
Anaissie, E
Badros, A
Cromer, J
Tricot, G
Citation: B. Barlogie et al., Thalidomide in the management of multiple myeloma, SEM HEMATOL, 38(3), 2001, pp. 250-259
Authors:
Shaughnessy, JD
Barlogie, B
Citation: Jd. Shaughnessy et B. Barlogie, Developmental therapeutics for multiple myeloma - A road map for the future, SEM HEMATOL, 38(3), 2001, pp. 295-297
Authors:
Barlogie, B
Citation: B. Barlogie, High-dose therapy and innovative approaches to treatment of multiple myeloma, SEM HEMATOL, 38(2), 2001, pp. 21-27
Authors:
Lim, SH
Badros, A
Lue, C
Barlogie, B
Citation: Sh. Lim et al., Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma, CANCER, 91(5), 2001, pp. 900-908
Authors:
Badros, A
Barlogie, B
Siegel, E
Roberts, J
Langmaid, C
Zangari, M
Desikan, R
Shaver, MJ
Fassas, A
McConnell, S
Muwalla, F
Barri, Y
Anaissie, E
Munshi, N
Tricot, G
Citation: A. Badros et al., Results of autologous stem cell transplant in multiple myeloma patients with renal failure, BR J HAEM, 114(4), 2001, pp. 822-829
Authors:
Badros, A
Barlogie, B
Siegel, E
Morris, C
Desikan, R
Zangari, M
Fassas, A
Anaissie, E
Munshi, N
Tricot, G
Citation: A. Badros et al., Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years, BR J HAEM, 114(3), 2001, pp. 600-607
Authors:
Wilson, CS
Butch, AW
Lai, R
Medeiros, LJ
Sawyer, JR
Barlogie, B
McCourty, A
Kelly, K
Brynes, RK
Citation: Cs. Wilson et al., Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy, BR J HAEM, 112(3), 2001, pp. 776-782
Authors:
Chiriva-Internati, M
Du, J
Cannon, M
Barlogie, B
Yi, Q
Citation: M. Chiriva-internati et al., Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway, BR J HAEM, 112(2), 2001, pp. 410-420
Authors:
Sawyer, JR
Lukacs, JL
Thomas, EL
Swanson, CM
Goosen, LS
Sammartino, G
Gilliland, JC
Munshi, NC
Tricot, G
Shaughnessy, JD
Barlogie, B
Citation: Jr. Sawyer et al., Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma, BR J HAEM, 112(1), 2001, pp. 167-174
Authors:
Desikan, KR
Tricot, G
Munshi, NC
Anaissie, E
Spoon, D
Fassas, A
Toor, A
Zangari, M
Badros, A
Morris, C
Vesole, DH
Siegel, D
Jagannath, S
Barlogie, B
Citation: Kr. Desikan et al., Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone, BR J HAEM, 112(1), 2001, pp. 242-247
Authors:
Zangari, M
Anaissie, E
Barlogie, B
Badros, A
Desikan, R
Gopal, AV
Morris, C
Toor, A
Siegel, E
Fink, L
Tricot, G
Citation: M. Zangari et al., Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy, BLOOD, 98(5), 2001, pp. 1614-1615
Authors:
Badros, A
Barlogie, B
Morris, C
Desikan, R
Martin, SR
Munshi, N
Zangari, M
Mehta, J
Toor, A
CottlerFox, M
Fassas, A
Aniassie, E
Schichman, S
Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (vol 97, pg 2574, 2001), BLOOD, 98(2), 2001, pp. 271-271
Authors:
Barlogie, B
Desikan, R
Eddlemon, P
Spencer, T
Zeldis, J
Munshi, N
Badros, A
Zangari, M
Anaissie, E
Epstein, J
Shaughnessy, J
Ayers, D
Spoon, D
Tricot, G
Citation: B. Barlogie et al., Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 studyof 169 patients, BLOOD, 98(2), 2001, pp. 492-494
Authors:
Dhodapkar, MV
Jacobson, JL
Gertz, MA
Rivkin, SE
Roodman, GD
Tuscano, JM
Shurafa, M
Kyle, RA
Crowley, JJ
Barlogie, B
Citation: Mv. Dhodapkar et al., Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003), BLOOD, 98(1), 2001, pp. 41-48
Authors:
Shaughnessy, J
Gabrea, A
Qi, Y
Brents, L
Zhan, FH
Tian, EM
Sawyer, J
Barlogie, B
Bergsagel, PL
Kuehl, M
Citation: J. Shaughnessy et al., Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma, BLOOD, 98(1), 2001, pp. 217-223
Authors:
Badros, A
Barlogie, B
Morris, C
Desikan, R
Martin, SR
Munshi, N
Zangari, M
Toor, A
Cottler-Fox, M
Fassas, A
Aniassie, E
Schichman, S
Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions, BLOOD, 97(9), 2001, pp. 2574-2579
Authors:
Wen, YJ
Barlogie, B
Yi, Q
Citation: Yj. Wen et al., Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells, BLOOD, 97(6), 2001, pp. 1750-1755
Authors:
Alexanian, R
Anderson, K
Barlogie, B
Berenson, J
Dalton, WS
Kyle, RA
Citation: R. Alexanian et al., Sydney E. Salmon, CLIN CANC R, 6(1), 2000, pp. 316-316
Authors:
Alexanian, R
Anderson, K
Barlogie, B
Berenson, J
Dalton, WS
Kyle, RA
Citation: R. Alexanian et al., Sydney E. Salmon, MD - In Memoriam, J CL ONCOL, 18(1), 2000, pp. 1-2
Authors:
Desikan, KR
Tricot, G
Dhodapkar, M
Fassas, A
Siegel, D
Vesole, DH
Jagannath, S
Singhal, S
Mehta, J
Spoon, D
Anaissie, E
Barlogie, B
Munshi, N
Citation: Kr. Desikan et al., Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone, BONE MAR TR, 25(5), 2000, pp. 483-487
Authors:
Munshi, NC
Desikan, KR
Barlogie, B
Citation: Nc. Munshi et al., Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies, SEM HEMATOL, 37(1), 2000, pp. 15-21
Authors:
Alexanian, R
Anderson, KC
Barlogie, B
Stirling, DI
Thomas, DA
Citation: R. Alexanian et al., Thalidomide in hematologic malignancies: Future directions, SEM HEMATOL, 37(1), 2000, pp. 35-39